Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase
- 1 August 2017
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 137, 29-50
Abstract
No abstract availableKeywords
Funding Information
- National Nature Science Foundation of China (81473083)
This publication has 66 references indexed in Scilit:
- The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its deathCell Research, 2016
- Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 UbiquitinationMolecular Cancer Research, 2016
- Interferon-γ-induced p27KIP1 binds to and targets MYC for proteasome-mediated degradationOncotarget, 2015
- Regulating the 20S Proteasome Ubiquitin-Independent Degradation PathwayBiomolecules, 2014
- Targeting Notch signaling pathway to overcome drug resistance for cancer therapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
- RING Domain E3 Ubiquitin LigasesAnnual Review of Biochemistry, 2009
- Multiple Proteasome-Interacting Proteins Assist the Assembly of the Yeast 19S Regulatory ParticleCell, 2009
- Regulation of CD8 + T Cell Development by Thymus-Specific ProteasomesScience, 2007
- A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibCancer Cell, 2005
- Lessons from the discovery ofthe ubiquitin systemTrends in Biochemical Sciences, 1996